Attitudes of patients and family members towards implantable psychiatric medication.
BACKGROUND
Medication is a necessary part of treatment for severe psychiatric illnesses such as schizophrenia and nonadherence to prescribed medication is one of the most important public health issues in psychiatry today. The devastating consequences of nonadherence have motivated the development of novel therapeutic strategies, including a new long-term implantable medication delivery system.


METHODS
The current study assesses attitudes towards implantable medication in psychiatric patients and their family members. Patients included in the study had diagnoses of Schizophrenia, Schizoaffective Disorder, Mood or Anxiety related disorders.


RESULTS
49.62% of patients and 74.47% of family members endorse support for implantable medication.


CONCLUSIONS
This study demonstrates that implants may be an acceptable alternative to oral and injectable medication for a subset of psychiatric patients and their families.
Stanley Center for Experimental Therapeutics in Psychiatry, Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States.
Mary E
ME
Dankert
Colleen M
CM
Brensinger
Kayla L
KL
Metzger
Chunbo
C
Li
Svetlinka G
SG
Koleva
Andrea
A
Mesén
Béatrice
B
Laprade
Tjhin
T
Wiguna
Changsu
C
Han
Saeed
S
Farooq
W Emanuel
WE
Severus
Jocelyn G
JG
Gayares
Jens M
JM
Langosch
Xavier
X
Lallart
Masaru
M
Tateno
Adriana
A
Mihai
Sudha R N
SR
Nair
Robert
R
Belmaker
Janusz
J
Rybakowski
Björn
B
Owe-Larsson
John M
JM
Kane
Eve C
EC
Johnstone
Donald J
DJ
MacIntyre
Sameer
S
Malhotra
Ana
A
González-Pinto
Fernando
F
Mosquera
Suzann M
SM
Babb
Ehsan
E
Habib pour
Seyedeh Sedigheh
SS
Fatemi
Charles
C
Swanson
Caleb
C
Adler
Allan
A
Young
Fumiko
F
Hoeft
Kandiah
K
Sivakumar
Petya D
PD
Radoeva
Elise A
EA
Lallart
Warren B
WB
Bilker
Steven J
SJ
Siegel
D000328:Adult; D001294:Attitude to Health; D003024:Clozapine / Q000008:administration & dosage / Q000627:therapeutic use; D003431:Cross-Cultural Comparison; D003625:Data Collection / Q000706:statistics & numerical data; D004343:Drug Implants / Q000008:administration & dosage / Q000627:therapeutic use*; D005190:Family / Q000523:psychology*; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology*; D008875:Middle Aged; D019964:Mood Disorders / Q000188:drug therapy / Q000523:psychology; D010349:Patient Compliance; D011618:Psychotic Disorders / Q000188:drug therapy / Q000523:psychology; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D014481:United States
D004343:Drug Implants; D011619:Psychotropic Drugs; D003024:Clozapine; D006220:Haloperidol